Products
Suppliers
Sourcing Requests

Visitor
Exhibitor
Advertiser
Supplier
Buyer

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Buyer
Suppliers
Advertiser
Exhibitor
Visitor

You are here: Home > Content Hub

Content Hub

Webinars

Pharma Sources Insight

Industry Reports

PharmaVibe

GMP Inspection Situation on Drug Manufacturing Equipment and Management Experience of Russian Inspectorate

Date: 19 October 2020

Speaker: Ivan Guliaev
PhD., Head of the Training and Development Division of Inspectorate
Federal State Institution «State Institute of Drugs and Good Practices», Russia

How Indian API Register in China

Date: 22 June 2020

Speaker: Chengpei Liu
Registration Manager | China Chimopharma

Best Practices in Pharmaceutical Remote Audits During COVID-19 and Beyond

Date: 21 June 2020

Speaker: Jim Fries
CEO of Rx-360

Pharmaceutical Market in China Policy Reform, Impacts and Opportunities

Date: 18 June 2020

Speaker: Dr. Annie Siu
Principal Consultant (Informa)

2019 Deals Review and Deals in China

Date: 18 June 2020

Speaker: Tina Zhao
Life Sciences Solution Consultant, Clarivate

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page

Pharma Sources Insight

Pharma Sources Insight January 2025: What are Reshaping Pharma's Future?

Download for Free

Pharma Sources Insight June 2024: Globalization on the Go

Download for Free

Pharmaceutical Industry in 2024: Flexible Production, Innovative Drugs and Personalized Medicine

Download for Free

Industry Report

Asia Pacific as a Clinical Trials Powerhouse

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

Pharma R&D Annual Review 2022: Navigating the Landscape

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

The Annual Clinical Trials Round-up 2021-Clinical Trials Resilience After Pandemic Disruptions

October 2022

Presented by

Informa Pharma Intelligence

Download

China Clinical Trials Landscape 2021

September 2021

Presented by

Informa Pharma Intelligence

Download

2021Sustainability in Pharma Packaging, Devices and Manufacturing Report

December 2021

Presented by

CPHI Online

Download

CPhI Pharma 2021 Annual Report- Golden Age for Discovery, Technology and Growth

December 2021

Presented by

CPHI Online

Download

CPhI China and IQVIA Market Prognosis 2021- 2025

September 2021

Presented by

CPhI and IQVIA team

Download

CCC 2020 - Blue Book on the internationalization of china's pharmaceutical industry

November 2020

Presented by

China Chamber of Commerce for Import & Export of Medicines &Health Products and China Office of Clarivate Analytics

Download

CPhI China Report 2020 - IQVIA

September 2020

Presented by

CPhI and IQVIA team

Download

ANNUAL HIGHLIGHTS OF CHINA'S HEALTHCARE INDUSTRY

February 2020

Presented by

China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)

Download

GBI - Year in Review 2019 China's new drug approvals

January 2020

Presented by

Robert McTiernan

Download

Asia Pacific as a Clinical Trials Powerhouse

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

Pharma R&D Annual Review 2022: Navigating the Landscape

October 2022

Presented by

Citeline (Pharma Intelligence)

Download

The Annual Clinical Trials Round-up 2021-Clinical Trials Resilience After Pandemic Disruptions

October 2022

Presented by

Informa Pharma Intelligence

Download

China Clinical Trials Landscape 2021

September 2021

Presented by

Informa Pharma Intelligence

Download

2021Sustainability in Pharma Packaging, Devices and Manufacturing Report

December 2021

Presented by

CPHI Online

Download

CPhI Pharma 2021 Annual Report- Golden Age for Discovery, Technology and Growth

December 2021

Presented by

CPHI Online

Download

CPhI China and IQVIA Market Prognosis 2021- 2025

September 2021

Presented by

CPhI and IQVIA team

Download

CCC 2020 - Blue Book on the internationalization of china's pharmaceutical industry

November 2020

Presented by

China Chamber of Commerce for Import & Export of Medicines &Health Products and China Office of Clarivate Analytics

Download

CPhI China Report 2020 - IQVIA

September 2020

Presented by

CPhI and IQVIA team

Download

ANNUAL HIGHLIGHTS OF CHINA'S HEALTHCARE INDUSTRY

February 2020

Presented by

China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)

Download

GBI - Year in Review 2019 China's new drug approvals

January 2020

Presented by

Robert McTiernan

Download

PharmaVibe

The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases

#Drug Review #R&D #Business

EPISODE 30 | 16 MIN | 22 Nov. 2022

The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. Looking back on this week's pharma news, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases.

Play

NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China

#Drug Review #R&D #Business

EPISODE 29 | 14 MIN | 15 Nov. 2022

This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs.

Play

The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China

#Drug Review #R&D #Business

EPISODE 28 | 14 MIN | 08 Nov. 2022

This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products.

Play

The Marketing Declaration of HAISCO's Novel Analgesic for Diabetic Peripheral Neuralgia Treatment

#Drug Review #R&D #Business #Listing #COVID-19

EPISODE 27 | 13 MIN | 01 Nov. 2022

The marketing application of HAISCO's first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. While in the global markets, Simcere Pharmaceutical's SIM0237 had been approved for clinical use in the United States for the treatment of locally advanced unresectable or metastatic solid tumors. In terms of R&D, several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients.

Play

You can get more engaged!